- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sovaldi's Cost-Effectiveness is Being Overplayed
Bottom line: Sovaldi will not save the system money. It will cost money-a lot of money-to reduce premature mortality due to chronic hepatitis C infection.
"Research on the cost-effectiveness of Sovaldi is still in the early stages, but it appears that use of the drug has the potential to actually save money over the long run.” —New York Times UpShot column, Aug. 2
Nothing could be further from the truth.
A detailed analysis of cost-effectiveness studies, which appeared six years ago in the New England Journal of Medicine, found that about 1 in 5 medical interventions save money by reducing the need for other, more costly treatments. For instance, if you have elevated cholesterol and take statins, it reduces the risk of heart attack. A relatively cheap pill prevents a very costly intervention.
Read the full story here: http://bit.ly/1ymGM5S
Source: Modern Healthcare
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen
